ALMOF (Alphamab Oncology) Change In Receivables: $-11.44 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALMOF Alphamab Oncology ALMOF
12 GF Score
Price $1.02
GF Value $0.87
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Change In Receivables?

Alphamab Oncology ALMOF 12 Change In Receivables is $-11.44 Mil as of Dec. 2025. GuruFocus rates ALMOF with a GF Score™ of 12/100 and a GF Value™ of $0.87 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Alphamab Oncology's change in receivables for the quarter that ended in Dec. 2025 was $-5.02 Mil. It means Alphamab Oncology's Accounts Receivable increased by $5.02 Mil from Jun. 2025 to Dec. 2025 .

Alphamab Oncology's change in receivables for the fiscal year that ended in Dec. 2025 was $-11.56 Mil. It means Alphamab Oncology's Accounts Receivable increased by $11.56 Mil from Dec. 2024 to Dec. 2025 .

Alphamab Oncology's Accounts Receivable for the quarter that ended in Dec. 2025 was $8.80 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alphamab Oncology's Days Sales Outstanding for the six months ended in Dec. 2025 was 45.81.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alphamab Oncology's liquidation value for the six months ended in Dec. 2025 was $151.15 Mil.

Alphamab Oncology  (OTCPK:ALMOF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alphamab Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=8.795/35.04*91
=45.81

2. In Ben Graham's calculation of liquidation value, Alphamab Oncology's accounts receivable are only considered to be worth 75% of book value:

Alphamab Oncology's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=191.72-54.829+0.75 * 8.795+0.5 * 15.317
=151.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Change In Receivables Related Terms

Alphamab Oncology Change In Receivables Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Change In Receivables Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -3.48 3.70 3.37 -0.68 -11.56

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 -0.95 0.27 -6.41 -5.02
ALMOF
12GF Score
Alphamab Oncology ALMOF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-11.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-11.44 Mil mean?
Alphamab Oncology (ALMOF) has a Change In Receivables of $-11.44 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Alphamab Oncology and its competitors.
Is Alphamab Oncology's Change In Receivables too high?
Alphamab Oncology's current Change In Receivables is $-11.44 Mil. Overall, Alphamab Oncology has a GF Score™ of 12/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Change In Receivables compare to VRTX and REGN?
Alphamab Oncology's Change In Receivables of $-11.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Alphamab Oncology and its competitors. Alphamab Oncology's current Change In Receivables is $-11.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (ALMOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.02 — trading 17.4% above its estimated fair value. The current Change In Receivables is $-11.44 Mil. Alphamab Oncology's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Alphamab Oncology (ALMOF), the current Change In Receivables is $-11.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (ALMOF) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of $1.02 is trading 17.4% above its estimated GF Value™ of $0.87. GuruFocus considers Alphamab Oncology to be Modestly Overvalued.

Key valuation signals for ALMOF:

  • Change In Receivables: $-11.44 Mil
  • GF Value™: $0.87 vs. price of $1.02 (17.4% above fair value)
  • GF Score™: 12/100 with 4 warning signs

No single metric tells the full story. See the ALMOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
12GF Score

Get the complete analysis for ALMOF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price
$0.87
GF Value